

Clinical Trial Protocol

Iranian Registry of Clinical Trials

30 May 2026

Evaluation of treatment strategy Included : hydroxychloroquine ,naproxen and oseltamivir for outpatient patients with Covid 19

Protocol summary

Study aim

Determining the results of treatment strategy including oseltamivir, naproxen, hydroxychloroquine in outpatients with Covid 19

Design

Patients were treated with a treatment strategy after a certain diagnosis, based on clinical evidence and inflammatory examinations that did not have symptoms. Patients were divided into two groups in parallel; a group received only Hydroxychloroquine and Naproxen, and the second group, in addition to the two drugs, received Oseltamivir. both groups were treated to prevent the digestive effects of Pantoprazole therapeutic strategy by 20 mg twice, the symptoms and procedure of treatment of patient patients were followed.

Settings and conduct

Patients with Covid 19 referred to a specialized clinic for lung and office who receive oxygen saturation percentage less than 90% by receiving oxygen by reservation bag, provided the inclusion criteria, in two groups of 50 people as a control and intervention, The intervention group was treated with naproxen, hydroxychloroquine and oseltamivir and the second group were treated with naproxen hydroxychloroquine.

Participants/Inclusion and exclusion criteria

inclusion: Patients with Covid 19 coincide with disease confirmation Positive PCR test Bilateral lung involvement Having symptoms of the disease Minimum elementary literacy The patient should not participate in another trial. Oxygen saturation level below 90 ; exclusion: Lack of patient cooperation

Intervention groups

Intervention group: the three drugs Naproxen 500 mg twice daily, Hydroxychloroquine 200 mg twice daily, and Oseltamivir 75 mg twice daily for 5 days 5 days Control group: from two drugs Naproxen 500 mg twice, Hydroxychloroquine 200 mg twice a day

Main outcome variables

Status of symptoms

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20201202049566N1**

Registration date: **2021-01-22, 1399/11/03**

Registration timing: **retrospective**

Last update: **2021-01-22, 1399/11/03**

Update count: **0**

Registration date

2021-01-22, 1399/11/03

Registrant information

Name

akram asghari

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 25 3912 2000

Email address

aasgharii@muq.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-02-20, 1398/12/01

Expected recruitment end date

2020-03-09, 1398/12/19

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of treatment strategy Included :
hydroxychloroquine ,naproxen and oseltamivir for
outpatient patients with Covid 19

2020-08-25, 1399/06/04

Ethics committee reference number
IR.MUQ.REC.1399.209

Public title

treatment strategy Included: hydroxychloroquine,
naproxen, and oseltamivir for outpatient patients with
Covid 19

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Patients with Covid 19 with concurrent disease
confirmation Positive PCR test Bilateral lung involvement
Having symptoms of the disease Oxygen saturation
level: below 90 does not participate in another trial least
basic literacy

Exclusion criteria:

Lack of cooperation

Age

From **12 years** old to **70 years** old

Gender

Both

Phase

N/A

Groups that have been masked

No information

Sample size

Target sample size: **150**

Randomization (investigator's opinion)

Not randomized

Randomization description

Blinding (investigator's opinion)

Not blinded

Blinding description

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics Committee of Qom University of Medical
Sciences

Street address

blv.beheshti

City

Qom

Province

Ghous

Postal code

3719964797

Approval date

Health conditions studied

1

Description of health condition studied

COVID-19

ICD-10 code

U07.1

ICD-10 code description

COVID-19, virus identified

Primary outcomes

1

Description

Having symptoms indicative of cough, shortness of
breath, fever

Timepoint

Daily - 14 days after treatment

Method of measurement

questionnaire

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: The patient is quarantined at home
for two weeks and uses two drugs, naproxen 500 mg
twice daily, hydroxychloroquine 200 mg twice daily, and
oseltamivir 75 mg twice daily for 5 days.

Category

Treatment - Drugs

2

Description

Control group: The patient is quarantined at home for
two weeks and uses two drugs, naproxen 500 mg twice
daily, hydroxychloroquine 200 mg twice daily for 5 days.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Shahid Beheshti Hospital

Full name of responsible person

Seyed Hasan Adeli

Street address

Beheshti Blv
City
Qom
Province
Ghoum
Postal code
37719964797
Phone
+98 25 3612 2000
Email
adeli@muq.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity
Ghoum University of Medical Sciences
Full name of responsible person
Ehsan Sharifipour
Street address
Safashahr
City
Qom
Province
Ghoum
Postal code
3719964797
Phone
+98 61 22000
Email
ehsansharifipour@gmail.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Ghoum University of Medical Sciences
Proportion provided by this source
30
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact

Name of organization / entity
Ghoum University of Medical Sciences
Full name of responsible person
Akram Asghari
Position
Assistant professor
Latest degree

Subspecialist
Other areas of specialty/work
Internal Medicine
Street address
Beheshti hospital
City
Qom
Province
Ghoum
Postal code
3719964797
Phone
+98 25 3912 2000
Fax
Email
aasgharii@muq.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity
Ghoum University of Medical Sciences
Full name of responsible person
Akram Asghari
Position
Assistant professor
Latest degree
Subspecialist
Other areas of specialty/work
Internal Medicine
Street address
beheshti blv
City
Qom
Province
Ghoum
Postal code
3719964797
Phone
+98 25 3612 2000
Email
aasgharii@muq.ac.ir

Person responsible for updating data

Contact

Name of organization / entity
Ghoum University of Medical Sciences
Full name of responsible person
akram asghari
Position
Assistant professor
Latest degree
Subspecialist
Other areas of specialty/work
Internal Medicine
Street address
beheshti blv
City
Qom
Province

Ghous

Postal code

3719964797

Phone

+98 25 3612 2000

Email

aasgharii@muq.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Not applicable

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to

make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Not applicable

Title and more details about the data/document

-

When the data will become available and for how long

-

To whom data/document is available

-

Under which criteria data/document could be used

-

From where data/document is obtainable

-

What processes are involved for a request to access data/document

-

Comments

-